PIK3CA and breast carcinoma: For example, Breast carcinoma patients with variant PIK3CA p.Glu453Lys are sensitive to the FDA-approved therapy Alpelisib + Fulvestrant based on the result of a Phase III clinical trial SOLAR-1 (NCT02437318).